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Conclusion: Although the ostial strut of LCX was not opened after LM crossover
stenting, the clinical outcome of this strategy demonstrated safe and favorable clinical
outcomes.
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Background: The long-term outcomes and its predictive factors after crush technique
for bifurcation lesions remain uncertain.
Methods: Consecutive 273 patients with 278 bifurcation lesions who received crush
stenting were prospectively enrolled. Final kissing balloon dilatation (FKBD) after
crushing was attempted in all patients. Guidance of intravascular ultrasound was
attempted in all procedures. Angiographic analysis was performed using the dedicated
bifurcation software. Analysis was performed per a lesion basis.
Results: FKBD was successfully performed in 94.2% of lesions and non-compliant
balloon was used in 45.3% for the main branch and 36.7% for the side branch. For the
median of 18 months follow-up, major adverse cardiac events (MACE) including
death, myocardial infarction, and target vessel revascularization (TVR) occurred in 21
lesions. Freedom from death, myocardial infarction, TVR and MACE were 97.0%,
96.3%, 83.7% and 80.4%, respectively. Angiographic follow-up was performed in
72.7% of lesions and angiographic restenosis was identified in 9.4% of lesions. In
multivariate Cox model, diabetes mellitus FKBD and pre-procedure MLD at proximal
main branch were independently associated with MACE.
Conclusion: Crush technique under the guidance of intravascular ultrasound has
favorable long-term outcomes when FKBD is successfully performed.
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Background: ST-segment elevation acute myocardial infarction (STEMI) due to
unprotected left main coronary occlusion (ULMCO) is a dramatic and catastrophic
entity with high risk of out-of-hospital sudden death. Therefore very few data have
been published regarding the effectiveness of primary percutaneous coronary
intervention (PPCI) in this group of patients. The objective was to determine the
incidence and predictors of in-hospital mortality.
Methods: Single-center retrospective study of 2018 consecutive patients who
underwent PPCI for STEMI from January 2006 to May 2011
Results: Among 2018 STEMI patients admitted for PPCI, 32 (1.58%) had acute
subtotal or total ULMCO. Mean age was 63.9 ± 15.1 years, 23 (72%) were male, 6
(19%) had diabetes, 10 (31%) smokers. Angiography showed 4 (12.5%) proximal, 3
(9.3%) middle, 22 (69%) distal and 3 (9.3%) diffuse ULMCO. Initial Killip class I-III
in 18 (56.2%) and Killip class IV in 14 (43.8%). In-hospital mortality occurred in 16
(50%) patients and only one (3.1%) at 1 year. Univariate analysis determined type of
stent deployed, severity of stenosis and Killip class at admission as predictors of in-
hospital mortality. The Cox regression model identified as independent predictor of
in-hospital mortality only Killip class at admission (RR 2.47 [95% CI 1.25 - 4.89]).
Conclusion: Among patients with STEMI due to thrombotic ULMCO undergoing
primary angioplasty in our center, in-hospital mortality was 50%, but with very low
mortality at 1-year follow up. Only Killip class at admission was identified as
independent predictor of in-hospital mortality.
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Background: For the treatment of unprotected left main coronary artery (ULMCA)
disease, although coronary artery bypass grafting (CABG) is recommended by the
current practice guidelines, percutanous coronary intervention (PCI) with drug-eluting
stents (DES) has recently emerged as an alternative to CABG. However, there are
limited data regarding whether the newer generation DESs is associated with better
outcomes as compared with first generation DESs in treating ULMCA disease.
Methods: A total 162 patients (pts) who underwent PCI with DESs for ULMCA were
enrolled for current study. We compared angiographic and clinical outcomes of first
generation DESs [Paclitaxel-eluting stents (Taxus™) and Sirolimus-eluting stents
(Cypher™)] versus newer generations DESs [Zotarolimus-eluting stents (Endeavor
Resolute™) and Everolimus-eluting stents(Promus Element™ and Xience™).
Results: Baseline characteristics were similar between the two groups except that
newer generations DESs group had a higher male gender (84.2% vs.65%, p=0.025).
At index procedure, there was trend towards higher use of IVUS in newer generations
DESs group (64.9% vs. 47.6%, p=0.065) whereas more use of final kissing balloon in
first generation DESs group (44.4% vs. 28.9%, p=0.091). However, at six months,
there were no differences in major angiographic outcomes and similar results were
found in major clinical outcomes up to twelve months. Interestingly, the DES
associated aneurysms were found only after the first generation DESs implantation
(Table).
Conclusion: In the current study, there were no significant differences between first
& newer generations DESs at 6 months angiographic and 12 months clinical outcomes
following ULMCA intervention.
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